Refining Vancomycin Use in Early CDI - Summary - MDSpire

Refining Vancomycin Use in Early CDI

  • By

  • Julia Cipriano, MS, CMPP

  • March 4, 2026

  • 2 min

Share

Objective:

To evaluate the efficacy of a 4-week vancomycin pulse-and-taper regimen compared to a 2-week pulse regimen followed by placebo in preventing recurrence of Clostridioides difficile infection (CDI).

Key Findings:
  • The 4-week pulse-and-taper regimen had a 74% probability of being superior to the 2-week pulse regimen followed by placebo in preventing recurrence.
  • Recurrence rates by day 56 were 15% in the pulse-and-taper group vs 18% in the placebo group.
  • Recurrence rates by day 38 were 7% in the pulse-and-taper group vs 15% in the placebo group.
  • Adverse effects were uncommon in both treatment approaches.
Interpretation:

The pulse-and-taper regimen may represent a safe and effective option for delaying or preventing early CDI recurrence, although the observed differences may be influenced by delayed recurrences.

Limitations:
  • The trial was stopped early due to recruitment feasibility challenges.
  • Further evidence is needed to optimize therapy, including head-to-head trials against fidaxomicin.
Conclusion:

The findings suggest that a vancomycin pulse-and-taper regimen could be beneficial in managing CDI recurrences, warranting further research.

Original Source(s)

Related Content